Get the Stockscreener App
1.975
3.39%
0.055
Lineage Cell Therapeutics Inc stock is traded at $1.975, with a volume of 1.29M.
It is up +3.39% in the last 24 hours and up +17.46% over the past month.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
See More
Previous Close:
$1.92
Open:
$2
24h Volume:
1.29M
Relative Volume:
0.79
Market Cap:
$451.00M
Revenue:
$8.95M
Net Income/Loss:
$-21.49M
P/E Ratio:
-16.46
EPS:
-0.12
Net Cash Flow:
$-29.24M
1W Performance:
+13.43%
1M Performance:
+17.46%
6M Performance:
+304.52%
1Y Performance:
+143.32%
1-Day Range:
$1.96
$2.07
1-Week Range:
$1.66
$2.07
52-Week Range:
$0.3651
$2.07
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Name
Lineage Cell Therapeutics Inc
Sector
Industry
Phone
510-871-4188
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.975 | 438.44M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.50 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
638.23 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.90 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.39 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.24 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Initiated | Craig Hallum | Buy |
| Nov-02-22 | Initiated | Robert W. Baird | Outperform |
| Jun-14-22 | Initiated | B. Riley Securities | Buy |
| Aug-19-21 | Initiated | Noble Capital Markets | Outperform |
| Mar-31-21 | Initiated | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Stock (LCTX) Latest News
How to build a custom watchlist for Lineage Cell Therapeutics Inc.2025 Institutional Moves & AI Powered Buy and Sell Recommendations - newser.com
How hedge fund analytics apply to Lineage Cell Therapeutics Inc. stock2025 Support & Resistance & Risk Controlled Swing Alerts - newser.com
How institutional buying supports Lineage Cell Therapeutics Inc. stockPortfolio Performance Summary & Long-Term Capital Growth Ideas - newser.com
Is Lineage Cell Therapeutics Inc. stock undervalued historicallyMarket Movement Recap & Smart Investment Allocation Tips - newser.com
Will Lineage Cell Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Recap & Weekly Market Pulse Alerts - newser.com
Lineage Cell Therapeutics (LCTX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Is Lineage Cell Therapeutics Inc. stock cheap by valuation metrics2025 Technical Patterns & Expert Approved Momentum Ideas - newser.com
How Lineage Cell Therapeutics Inc. stock performs during market turbulence2025 Earnings Surprises & Stock Portfolio Risk Control - newser.com
Tools to assess Lineage Cell Therapeutics Inc.’s risk profileEarnings Recap Report & Fast Gain Stock Trading Tips - newser.com
Lineage Cell Therapeutics Hits New 52-Week High of $1.87 - Markets Mojo
How Lineage Cell Therapeutics Inc. stock moves on employment data2025 Momentum Check & Smart Money Movement Tracker - newser.com
Published on: 2025-11-02 02:45:07 - newser.com
Can Lineage Cell Therapeutics Inc. rally from current levelsJuly 2025 PostEarnings & High Return Trade Opportunity Guides - newser.com
How Lineage Cell Therapeutics Inc. stock reacts to Fed tightening - newser.com
Is Lineage Cell Therapeutics Inc. stock a top pick in earnings season2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Is Lineage Cell Therapeutics Inc. stock a momentum leaderQuarterly Earnings Report & AI Based Buy/Sell Signal Reports - newser.com
Will Lineage Cell Therapeutics Inc. stock outperform international peersBear Alert & Growth Focused Investment Plans - newser.com
Regression analysis insights on Lineage Cell Therapeutics Inc. performanceWeekly Market Report & Daily Chart Pattern Signals - newser.com
Why hedge funds are buying Lineage Cell Therapeutics Inc. stockQuarterly Trade Report & Smart Swing Trading Techniques - newser.com
Published on: 2025-11-02 04:56:29 - newser.com
Published on: 2025-11-01 02:10:50 - newser.com
Tools to monitor Lineage Cell Therapeutics Inc. recovery probabilityIPO Watch & Risk Controlled Swing Alerts - newser.com
Lineage Cell Therapeutics to release Q3 2025 results, hosts business update call - Traders Union
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 - Business Wire
Published on: 2025-10-30 05:00:08 - newser.com
Published on: 2025-10-29 06:15:34 - newser.com
Published on: 2025-10-29 06:04:11 - newser.com
Published on: 2025-10-29 04:52:09 - newser.com
Lineage Cell Therapeutics Inc Stock (LCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):